Metabolic reprogramming is now recognized as a hallmark of aggressive cancers, but pinpointing the molecular switches that redirect cellular metabolism toward tumor-supportive pathways has remained elusive. A newly identified crosstalk between a cell-cycle kinase and amino acid biosynthesis may represent exactly such a switch — with implications for how castration-resistant prostate cancer sustains its growth advantage.
Published in PNAS, the research identifies a previously undescribed functional relationship between PLK1 (Polo-like kinase 1) — a serine/threonine kinase central to mitotic regulation — and PHGDH (phosphoglycerate dehydrogenase), the rate-limiting enzyme in the de novo serine synthesis pathway. The team demonstrates that PLK1 directly phosphorylates PHGDH, an event that suppresses the enzyme's canonical biosynthetic activity. Rather than simply disabling serine production, this phosphorylation event appears to redirect metabolic flux, constituting a form of metabolic reprogramming that advanced prostate cancer cells exploit for growth and survival. The finding positions PLK1 not merely as a cell-cycle checkpoint regulator but as a metabolic co-regulator in oncogenesis.
This mechanistic discovery sits at the intersection of two well-studied but previously siloed fields: PLK1 inhibitor development and cancer metabolism. PLK1 inhibitors such as volasertib have been clinically evaluated but have shown limited single-agent efficacy, partly because resistance mechanisms are poorly understood. If PLK1-driven PHGDH phosphorylation is a key survival pathway in advanced prostate cancer — particularly the castration-resistant form, where treatment options narrow sharply — then combined inhibition strategies targeting both kinase signaling and serine metabolism could prove synergistic. However, critical caveats apply: the excerpt describes a mechanistic cell and molecular study; whether these findings translate to patient tumors at meaningful clinical scale remains unestablished. Validation in patient-derived organoids and in vivo models, followed by biomarker studies in clinical cohorts, will be essential steps. This finding is best characterized as mechanistically novel and potentially actionable, but preclinical in scope.